SGMT AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
SGMT Current Performance
0.59%
Sagimet biosciences inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to SGMT
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
OGN | Organon & co | 2 | 4 | 4 | 3 | 2 | |
STTK | Shattuck labs, inc | 2 | 2 | 4 | 3 | 1 | |
CMPS | Compass pathways plc - adr | 1 | 3 | 2 | 1 | 1 | |
CDMO | Avid bioservices inc | 1 | 5 | 2 | 3 | 1 | |
VCEL | Vericel corp | 3 | 4 | 4 | 2 | 1 |
- OGN Organon & coValue 2Trend 4Swing Trading 4Whale Interest 3Dividend 2See more
SGMT Profile
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.